



CARNEGIE FUND II

**FONDS COMMUN DE PLACEMENT
INCORPORATED UNDER LUXEMBOURG LAW**

UNAUDITED SEMI-ANNUAL REPORT

JUNE 30, 2011

Subscriptions are only valid if made on the basis of the current prospectus accompanied by the latest annual report and the latest semi-annual report if published after the annual report

CARNEGIE FUND II

TABLE OF CONTENTS

GENERAL INFORMATION

Management and Administration	3
Board of Directors of the Management Company	3

FINANCIAL STATEMENTS

Statement of Net Assets	4 - 5
Net Asset Value per Unit	4 - 5
Statement of Operations and Changes in Net Assets	6 - 7
Statement of Changes in Number of Units Outstanding	8 - 9

SECURITIES PORTFOLIOS

Carnegie Fund II - Biotechbridge Sub-Fund	10
Carnegie Fund II - Biotechnology Sub-Fund	11 - 12
Carnegie Fund II - Fund of Funds International	13 - 14
Carnegie Fund II - Private Equity I Sub-Fund	15
Carnegie Fund II - Private Equity II Sub-Fund	16
Carnegie Fund II - Swedish Large Cap Sub-Fund	17 - 18
Carnegie Fund II - Swedish Small Cap Sub-Fund	19 - 20

NOTES TO THE FINANCIAL STATEMENTS	21 - 24
-----------------------------------	---------

CARNEGIE FUND II

MANAGEMENT AND ADMINISTRATION

MANAGEMENT COMPANY

Carnegie Fund Management Company S.A.
5, Place de la Gare
L-1616 Luxembourg

CUSTODIAN

Banque Carnegie Luxembourg S.A.
5, Place de la Gare
L-1616 Luxembourg

CENTRAL ADMINISTRATION AGENT

Carnegie Fund Management Company S.A.
5, Place de la Gare
L-1616 Luxembourg

LEGAL ADVISOR

Bonn Schmitt Steichen
22-24, rives de Clausen
L-2165 Luxembourg

INVESTMENT MANAGERS

Carnegie Investment Bank AB
Regeringsgatan 56
S - 103 38 Stockholm, Sweden

Carnegie Asset Management
Fondsmæglerselskab A/S
Denmark, Sweden Branch
Blasieholmsgatan 5
S-103 94 Stockholm, Sweden

AUDITOR

PricewaterhouseCoopers S.à r.l.
400, Route d'Esch
L-1471 Luxembourg

BOARD OF DIRECTORS OF THE MANAGEMENT COMPANY

CHAIRMAN :

Claes-Johan GEIJER
Managing Director
Banque Carnegie Luxembourg S.A.
Luxembourg

DIRECTORS :

Bruno FREREJEAN
Co-Managing Director
Banque Carnegie Luxembourg S.A.
Luxembourg

Vincent GRUSELLE
Managing Director
Carnegie Fund Management Company S.A.
Luxembourg

CARNEGIE FUND II

STATEMENT OF NET ASSETS AS AT JUNE 30, 2011

	COMBINED (SEK)	BIOTECHBRIDGE SUB-FUND (EUR)	BIOTECHNOLOGY SUB-FUND (EUR)
ASSETS			
Securities portfolio at market value (Note 2.1)	1,495,163,909.64	0.00	12,644,654.08
Cash at banks and liquidities	41,343,422.77	0.00	0.00
OTHER ASSETS			
Subscriptions receivable	3,410,291.68	0.00	0.00
Dividends receivable (Note 2.4)	211,186.60	0.00	0.00
Total Other Assets	3,621,478.28	0.00	0.00
Total Assets	1,540,128,810.69	0.00	12,644,654.08
LIABILITIES			
Performance fee payable (Note 10)	(6,526,728.80)	0.00	0.00
Redemptions payable	(2,337,820.67)	0.00	0.00
Bank borrowings (Note 6)	(3,726,667.53)	0.00	(355,955.48)
Taxe d'abonnement payable (Note 4)	(176,149.25)	0.00	(1,531.74)
Brokers payable	(111,889.48)	0.00	0.00
Unrealised loss on forward foreign exchange contracts (Note 5)	(751.72)	0.00	0.00
Total Liabilities	(12,880,007.45)	0.00	(357,487.22)
NET ASSET VALUE	1,527,248,803.24	0.00	12,287,166.86

NET ASSET VALUE PER UNIT AS AT JUNE 30, 2011

	BIOTECHBRIDGE SUB-FUND (EUR)	BIOTECHNOLOGY SUB-FUND (EUR)
Net Asset Value	0.00	12,287,166.86
Net Asset Value per unit	0.00	9.52

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II

STATEMENT OF NET ASSETS AS AT JUNE 30, 2011

FUND OF FUNDS INTERNATIONAL (USD)	PRIVATE EQUITY I SUB-FUND (EUR)	PRIVATE EQUITY II SUB-FUND (EUR)	SWEDISH LARGE CAP SUB-FUND (SEK)	SWEDISH SMALL CAP SUB-FUND (SEK)
114,648,695.79	36,285,349.91	7,869,455.39	136,832,935.10	113,203,578.30
1,961,968.51	2,509,611.65	29,298.80	3,622,763.72	2,070,098.65
139,436.09	0.00	207,037.44	0.00	633,153.77
33,386.66	0.00	0.00	0.00	0.00
172,822.75	0.00	207,037.44	0.00	633,153.77
116,783,487.05	38,794,961.56	8,105,791.63	140,455,698.82	115,906,830.72
0.00	(713,023.16)	0.00	0.00	0.00
(3,161.82)	0.00	0.00	(15,241.15)	(2,302,579.50)
(23,579.32)	0.00	0.00	(127,453.26)	(191,789.71)
(12,260.11)	(4,747.20)	(1,010.45)	(17,654.78)	(14,219.25)
0.00	0.00	0.00	0.00	(111,889.48)
(118.84)	0.00	0.00	0.00	0.00
(39,120.09)	(717,770.36)	(1,010.45)	(160,349.19)	(2,620,477.94)
116,744,366.96	38,077,191.20	8,104,781.18	140,295,349.63	113,286,352.78

NET ASSET VALUE PER UNIT AS AT JUNE 30, 2011

FUND OF FUNDS INTERNATIONAL (USD)	PRIVATE EQUITY I SUB-FUND (EUR)	PRIVATE EQUITY II SUB-FUND (EUR)	SWEDISH LARGE CAP SUB-FUND (SEK)	SWEDISH SMALL CAP SUB-FUND (SEK)
116,744,366.96	38,077,191.20	8,104,781.18	140,295,349.63	113,286,352.78
13.53	127.44	77.58	116.22	125.92

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II

**STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS
FOR THE PERIOD ENDED JUNE 30, 2011**

	COMBINED (SEK) (i)	BIOTECHBRIDGE SUB-FUND (EUR)	BIOTECHNOLOGY SUB-FUND (EUR)
INCOME			
Dividends, net (Note 2.4)	5,441,540.99	0.00	7,091.26
Bank interest	39,839.34	0.00	0.00
Total Income	5,481,380.33	0.00	7,091.26
EXPENSES			
Management fee (Note 9)	(2,701,215.29)	0.00	(65,613.53)
Performance fee (Note 10)	(6,526,728.80)	0.00	0.00
Taxe d'abonnement (Note 4)	(317,926.40)	0.00	(2,992.47)
Bank interest	(97,060.68)	0.00	(9,765.96)
Total Expenses	(9,642,931.16)	0.00	(78,371.96)
Net profit/(loss) from investments	(4,161,550.83)	0.00	(71,280.70)
Net realised profit on sales of investments (Note 2.2)	18,270,591.94	0.00	287,652.51
Net profit/(loss) on foreign exchange (Note 2.3)	(1,050,472.99)	0.00	(692,047.08)
Net realised profit/(loss)	13,058,568.12	0.00	(475,675.27)
Variation in net unrealised appreciation/depreciation on investments	40,929,144.18	0.00	1,044,435.45
Variation in net unrealised loss on forward foreign exchange contracts	224,142.00	0.00	0.00
Increase/(decrease) in net assets as a result of operations	54,211,854.30	0.00	568,760.18
Subscriptions	849,799,909.01	0.00	14.73
Redemptions	(291,091,965.76)	0.00	(95,364.74)
Increase in net assets	612,919,797.56	0.00	473,410.17
Net assets at the beginning of the period (i)	914,329,005.68	0.00	11,813,756.69
NET ASSETS AT THE END OF THE PERIOD	1,527,248,803.24	0.00	12,287,166.86

Notes:

- (i) Net assets at the beginning of the year were translated at the exchange rate ruling as at June 30, 2011. The same net assets when translated at EUR = SEK 9.01250000, and USD = SEK 6.71772510 the exchange rates ruling as at December 31, 2010 reflect a figure of SEK 931,930,040.31.

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II

**STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS
FOR THE PERIOD ENDED JUNE 30, 2011**

FUND OF FUNDS INTERNATIONAL (USD)	PRIVATE EQUITY I SUB-FUND (EUR)	PRIVATE EQUITY II SUB-FUND (EUR)	SWEDISH LARGE CAP SUB-FUND (SEK)	SWEDISH SMALL CAP SUB-FUND (SEK)
424,728.07	0.00	0.00	973,580.84	1,716,441.30
0.00	995.31	25.03	5,144.07	25,355.49
424,728.07	995.31	25.03	978,724.91	1,741,796.79
(122,325.61)	0.00	0.00	(484,978.15)	(841,869.11)
0.00	(713,023.16)	0.00	0.00	0.00
(23,173.19)	(8,465.65)	(1,700.49)	(24,223.27)	(26,672.96)
(1,212.08)	0.00	0.00	0.00	0.00
(146,710.88)	(721,488.81)	(1,700.49)	(509,201.42)	(868,542.07)
278,017.19	(720,493.50)	(1,675.46)	469,523.49	873,254.72
0.00	1,243,330.97	0.00	1,383,270.97	2,873,310.59
1,212,453.09	(143,076.91)	(117,543.29)	448.33	67.88
1,490,470.28	379,760.56	(119,218.75)	1,853,242.79	3,746,633.19
712,908.95	3,604,143.85	600,233.69	(4,759,938.18)	(6,865,942.49)
35,434.79	0.00	0.00	0.00	0.00
2,238,814.02	3,983,904.41	481,014.94	(2,906,695.39)	(3,119,309.30)
59,377,067.17	4,217,303.92	4,154,440.86	95,412,133.13	302,167,673.88
(5,988,630.69)	0.00	0.00	(9,686,694.73)	(242,651,385.43)
55,627,250.50	8,201,208.33	4,635,455.80	82,818,743.01	56,396,979.15
61,117,116.46	29,875,982.87	3,469,325.38	57,476,606.62	56,889,373.63
116,744,366.96	38,077,191.20	8,104,781.18	140,295,349.63	113,286,352.78

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II

**STATEMENT OF CHANGES IN NUMBER OF UNITS OUTSTANDING
FOR THE PERIOD ENDED JUNE 30, 2011**

	BIOTECHBRIDGE SUB-FUND	BIOTECHNOLOGY SUB-FUND
Units outstanding at January 1, 2011	188,707.3450	1,299,864.7948
Units issued	0.0000	1.6703
Units redeemed	0.0000	(9,759.6476)
Units outstanding at June 30, 2011	188,707.3450	1,290,106.8175

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II

**STATEMENT OF CHANGES IN NUMBER OF UNITS OUTSTANDING
FOR THE PERIOD ENDED JUNE 30, 2011**

FUND OF FUNDS INTERNATIONAL	PRIVATE EQUITY I SUB-FUND	PRIVATE EQUITY II SUB-FUND	SWEDISH LARGE CAP SUB-FUND	SWEDISH SMALL CAP SUB-FUND
4,676,606.4234	260,809.8226	47,519.0267	468,480.1532	452,737.4973
4,401,373.8867	37,976.2832	56,944.8976	822,084.9111	2,367,914.8704
(449,578.9835)	0.0000	0.0000	(83,397.3705)	(1,920,981.0021)
8,628,401.3266	298,786.1058	104,463.9243	1,207,167.6938	899,671.3656

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - BIOTECHBRIDGE SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (EUR)	% OF NET ASSETS
Other Transferable Securities			
Shares & Warrants			
	<u>Canada</u>		
3,489,121	Genizon BioSciences Class E	0.00	0.00
133,603	Genizon BioSciences Class E December 20, 2012 Warrant	0.00	0.00
216,472	Genizon BioSciences Class H	0.00	0.00
		<u>0.00</u>	<u>0.00</u>
	TOTAL SHARES & WARRANTS	<u>0.00</u>	<u>0.00</u>
	TOTAL OTHER TRANSFERABLE SECURITIES	<u>0.00</u>	<u>0.00</u>
	TOTAL SECURITIES PORTFOLIO	<u>0.00</u>	<u>0.00</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - BIOTECHNOLOGY SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (EUR)	% OF NET ASSETS
Transferable Securities Admitted To An Official Exchange Listing			
Shares & Warrants			
	<u>Sweden</u>		
20,000	Active Biotech	182,441.88	1.48
61,864	Medivir B	887,044.44	7.22
100,000	Swedish Orphan Biovitrum	273,116.59	2.22
		<u>1,342,602.91</u>	<u>10.92</u>
	<u>United States of America</u>		
32,000	Alexion Pharmaceuticals	1,044,406.05	8.50
8,000	Amgen	322,548.55	2.63
29,000	Auxilium Pharmaceuticals	397,995.99	3.24
7,000	Biogen Idec	527,841.89	4.30
37,882	BioMarin Pharmaceutical	711,972.70	5.79
21,205	Celgene	889,610.64	7.24
16,000	Cepheid	382,447.65	3.11
75,000	Corcept Therapeutics	211,975.68	1.73
29,000	Gilead Sciences	833,867.74	6.79
15,297	Human Genome Sciences	265,115.58	2.16
6,138	Illumina	319,391.47	2.60
60,000	ImmunoGen	500,863.80	4.08
28,000	Momenta Pharmaceuticals	387,754.82	3.16
27,532	Myriad Genetics	437,399.41	3.56
17,286	Onyx Pharmaceuticals	434,688.37	3.54
5,000	Pharmasset	382,592.77	3.11
21,500	Regeneron Pharmaceuticals	831,414.55	6.77
49,137	Rigel Pharmaceuticals	314,427.90	2.56
17,500	Salix Pharmaceuticals	475,260.87	3.87
16,000	Seattle Genetics	231,967.38	1.89
6,000	Shire Pharmaceuticals Group ADR	386,510.95	3.15
19,000	Teva Pharmaceutical ADR	629,438.19	5.12
10,000	United Therapeutics Corporation	382,558.22	3.11
		<u>11,302,051.17</u>	<u>92.01</u>
	TOTAL SHARES & WARRANTS	<u>12,644,654.08</u>	<u>102.93</u>
	TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING	<u>12,644,654.08</u>	<u>102.93</u>
	TOTAL SECURITIES PORTFOLIO	<u>12,644,654.08</u>	<u>102.93</u>

CARNEGIE FUND II - BIOTECHNOLOGY SUB-FUND

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Healthcare	32.41
Pharmaceuticals & Cosmetics	70.52
	<u>102.93</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - FUND OF FUNDS INTERNATIONAL

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (USD)	% OF NET ASSETS
Transferable Securities Admitted To An Official Exchange Listing			
Investment Funds			
	<u>Germany</u>		
41,000	db x-trackers - DAX ETF	4,354,309.43	3.73
30,800	db x-trackers - EURO STOXX 50 ETF	1,335,337.57	1.14
		<u>5,689,647.00</u>	<u>4.87</u>
	<u>United Kingdom</u>		
330,000	iShares MSCI Japan Fund ETF	3,432,302.34	2.94
		<u>3,432,302.34</u>	<u>2.94</u>
	<u>United States of America</u>		
102,880	iShares MSCI Emerging Markets Index ETF	4,897,088.00	4.19
166,580	iShares S&P Global Consumer Discretionary Sector ETF	9,466,025.11	8.11
122,140	iShares S&P Global Consumer Staples Index ETF	8,141,852.40	6.97
100,040	iShares S&P Global Energy Sector Index ETF	4,176,670.00	3.58
58,230	SPDR S&P 500 ETF Trust	7,684,613.10	6.58
434,450	iShares MSCI ACWI Index ETF	20,962,212.50	17.96
92,300	PowerShares QQQ Nasdaq 100 ETF	5,265,715.00	4.51
		<u>60,594,176.11</u>	<u>51.90</u>
	TOTAL INVESTMENT FUNDS	<u>69,716,125.45</u>	<u>59.71</u>
	TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING	<u>69,716,125.45</u>	<u>59.71</u>

Other Transferable Securities

Investment Funds

	<u>Ireland</u>		
203,862	Gam Star - China Equity Fund	3,973,084.76	3.40
1,621,873	Gam Star - US All Cap Equity Fund	15,429,849.83	13.22
		<u>19,402,934.59</u>	<u>16.62</u>
	<u>Luxembourg</u>		
215,914	AllianceBernstein - American Growth Portfolio A	7,632,566.86	6.54
10,940	DnB NOR Fund - Navigator	1,863,665.37	1.60
162,327	Schroder ISF - European Equity Alpha A	9,102,528.13	7.80
		<u>18,598,760.36</u>	<u>15.94</u>

CARNEGIE FUND II - FUND OF FUNDS INTERNATIONAL

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (USD)	% OF NET ASSETS
Other Transferable Securities (continued)			
Investment Funds (continued)			
	<u>Norway</u>		
68,321	Skagen Kon-Tiki Fund	6,930,875.39	5.94
		<u>6,930,875.39</u>	<u>5.94</u>
	TOTAL INVESTMENT FUNDS	<u>44,932,570.34</u>	<u>38.50</u>
	TOTAL OTHER TRANSFERABLE SECURITIES	<u>44,932,570.34</u>	<u>38.50</u>
	TOTAL SECURITIES PORTFOLIO	<u>114,648,695.79</u>	<u>98.21</u>

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Investment Funds	98.21
	<u>98.21</u>

A statement of changes in the composition of the portfolio is available to Unitholders on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - PRIVATE EQUITY I SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (EUR)	% OF NET ASSETS
Investment Funds			
	<u>Guernsey</u>		
27,688,479.61	EQT V (No.1) Ltd Partnership	36,285,349.91	95.30
		<u>36,285,349.91</u>	<u>95.30</u>
	TOTAL INVESTMENT FUNDS	<u>36,285,349.91</u>	<u>95.30</u>
	TOTAL SECURITIES PORTFOLIO	<u>36,285,349.91</u>	<u>95.30</u>

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Investment Funds	95.30
	<u>95.30</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - PRIVATE EQUITY II SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (EUR)	% OF NET ASSETS
Investment Funds			
	<u>Guernsey</u>		
8,211,035.90	EQT Infrastructure (No.1) Ltd Partnership	7,869,455.39	97.10
		<u>7,869,455.39</u>	<u>97.10</u>
	TOTAL INVESTMENT FUNDS	<u>7,869,455.39</u>	<u>97.10</u>
	TOTAL SECURITIES PORTFOLIO	7,869,455.39	97.10
		<u><u>7,869,455.39</u></u>	<u><u>97.10</u></u>

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Investment Funds	97.10
	<u>97.10</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - SWEDISH LARGE CAP SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (SEK)	% OF NET ASSETS
Transferable Securities Admitted To An Official Exchange Listing			
Shares & Warrants			
	<u>Sweden</u>		
14,400	AstraZeneca	4,504,320.00	3.21
23,000	Atlas Copco A	3,831,800.00	2.73
2,400	Autoliv SDB	1,191,360.00	0.85
19,104	Avanza Bank Holding	3,687,072.00	2.63
53,900	ABB	8,791,090.00	6.27
9,900	Elekta B	2,950,200.00	2.10
140,440	Ericsson B	12,808,128.00	9.13
39,400	Fabege	2,494,020.00	1.78
52,800	Hennes & Mauritz B	11,457,600.00	8.17
10,967	Hexagon B	1,703,175.10	1.21
20,000	Intrum Justitia	1,850,000.00	1.32
23,000	Investor B	3,328,100.00	2.37
15,600	JM	2,312,700.00	1.65
7,400	Millicom International Cellular SDB	4,898,800.00	3.49
68,000	Net Entertainment B	4,114,000.00	2.93
130,800	Nordea Bank	8,835,540.00	6.30
44,000	Proffice B	1,447,600.00	1.03
73,400	Rezidor Hotel Group	2,928,660.00	2.09
59,900	Sandvik	6,708,800.00	4.78
36,700	Svenska Handelsbanken A	7,152,830.00	5.10
75,500	Swedbank A	7,987,900.00	5.69
28,200	Swedish Match	6,023,520.00	4.29
35,100	SCA B	3,113,370.00	2.22
93,660	SEB A	4,823,490.00	3.44
31,900	SKF B	5,856,840.00	4.17
13,400	TradeDoubler	540,020.00	0.38
104,000	Volvo B	11,492,000.00	8.19
		<u>136,832,935.10</u>	<u>97.52</u>
	TOTAL SHARES & WARRANTS	<u>136,832,935.10</u>	<u>97.52</u>
	TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING	<u>136,832,935.10</u>	<u>97.52</u>
	TOTAL SECURITIES PORTFOLIO	<u>136,832,935.10</u>	<u>97.52</u>

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Automobiles	9.04
Banking	20.53
Communications	13.00
Computer Software & Services	2.93
Engineering	1.21
Food, Drink & Tobacco	4.29
Forestry	2.22
Healthcare	2.10
Holding & Investment Companies	2.37
Hotels & Leisure	2.09
Machinery	17.95
Miscellaneous Finance	3.95
Miscellaneous Retail	8.17
Miscellaneous Services	1.03
Pharmaceuticals & Cosmetics	3.21
Real Estate & Construction	3.43
	<u>97.52</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

CARNEGIE FUND II - SWEDISH SMALL CAP SUB-FUND

SECURITIES PORTFOLIO AS AT JUNE 30, 2011

NOMINAL	SECURITY DESCRIPTION	MARKET VALUE (SEK)	% OF NET ASSETS
Transferable Securities Admitted To An Official Exchange Listing			
Shares & Warrants			
	<u>Sweden</u>		
24,300	AarhusKarlshamn	4,471,200.00	3.95
19,500	Addtech B	3,510,000.00	3.10
19,200	Avanza Bank Holding	3,705,600.00	3.27
26,100	Beijer Alma B	3,393,000.00	3.00
24,600	Betsson B	3,726,900.00	3.29
23,700	Bilia A	2,701,800.00	2.38
38,217	Bong Ljungdahl	1,056,700.05	0.93
59,413	Cision	2,792,411.00	2.46
57,800	Duni	3,554,700.00	3.14
72,125	DIBS Payment Services	3,534,125.00	3.12
81,143	Enea	3,529,720.50	3.12
56,484	Eolus Vind B	3,346,677.00	2.95
18,400	Hexpol B	3,339,600.00	2.95
92,600	HiQ International	3,435,460.00	3.03
22,000	Indutrade	4,400,000.00	3.88
37,000	Intrum Justitia	3,422,500.00	3.02
27,661	IFS B	3,284,743.75	2.90
28,400	JM	4,210,300.00	3.72
43,900	Lindab International	2,998,370.00	2.65
52,200	Loomis B	4,684,950.00	4.14
27,740	Medivir B	3,640,875.00	3.21
133,000	MQ Holding	3,178,700.00	2.81
61,750	Net Entertainment B	3,735,875.00	3.30
57,300	Nolato B	3,724,500.00	3.29
60,500	Nordic Mines	3,766,125.00	3.32
34,438	ProAct IT Group	4,545,816.00	4.01
31,300	Reijlerkoncernen B	2,237,950.00	1.98
85,000	Rezidor Hotel Group	3,391,500.00	2.99
48,786	Systemair	4,634,670.00	4.09
86,700	TradeDoubler	3,494,010.00	3.08
72,000	Transmode Holding	3,654,000.00	3.23
88,000	Uniflex	4,100,800.00	3.62
		<u>113,203,578.30</u>	<u>99.93</u>
	TOTAL SHARES & WARRANTS	<u>113,203,578.30</u>	<u>99.93</u>
	TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING	<u>113,203,578.30</u>	<u>99.93</u>
	TOTAL SECURITIES PORTFOLIO	<u>113,203,578.30</u>	<u>99.93</u>

CARNEGIE FUND II - SWEDISH SMALL CAP SUB-FUND

INDUSTRY SECTOR ANALYSIS AS AT JUNE 30, 2011

SECTOR DESCRIPTION	% OF NET ASSETS
Communications	6.31
Computer & Software Services	22.77
Construction & Building Materials	9.69
Electronic & Electricals	3.10
Engineering	6.83
Food, Drink & Tobacco	3.95
Healthcare	3.21
Hotels & Leisure	2.99
Mining & Metals	3.32
Miscellaneous Finance	6.29
Miscellaneous Goods	3.29
Miscellaneous Industrials	3.00
Miscellaneous Retail	8.33
Miscellaneous Services	12.20
Paper & Packaging	0.93
Real Estate & Construction	3.72
	<u>99.93</u>

A statement of changes in the composition of the portfolio is available to Unitholders free of charge on request from the Fund's registered office

The accompanying notes form an integral part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS

1 GENERAL

CARNEGIE FUND II is an Unincorporated Open-ended (since October, 2000) Collective Investment Fund ("Fonds Commun de Placement"), created on May 9, 2000, under Part II of the Luxembourg amended law of March 30, 1988 and does not qualify as an Undertaking for Collective Investment in Transferable Securities. Since December 30, 2003, CARNEGIE FUND II is governed by Part II of the Luxembourg amended law of December 20, 2002.

CARNEGIE FUND II ("the Fund") is an unincorporated co-proprietorship of its securities and other assets, managed by Carnegie Fund Management Company S.A. ("the Management Company"). The Management Company was incorporated in December 5, 1995 in Luxembourg as a "société anonyme". The assets of the Fund are segregated from those of the Management Company.

The Fund has the following Sub-Funds:

- Carnegie Fund II - Biotechbridge Sub-Fund (Closed-ended)
- Carnegie Fund II - Biotechnology Sub-Fund (Open-ended)
- Carnegie Fund II - Fund of Funds International (Open-ended)
- Carnegie Fund II - Private Equity I Sub-Fund (Closed-ended)
- Carnegie Fund II - Private Equity II Sub-Fund (Closed-ended)
- Carnegie Fund II - Swedish Large Cap Sub-Fund (Open-ended)
- Carnegie Fund II - Swedish Small Cap Sub-Fund (Open-ended)
- Carnegie Fund II - Carnegie Worldwide Long/Short Fund II (not yet opened for subscription)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Valuation of investments

- (a) The value of any cash at hand or on deposit, bills and demand notes and accounts receivable, prepaid expenses, dividends and interests declared or due but not yet collected will be deemed to be the full value thereof, unless it is unlikely that such values are received in full, in which case the value thereof will be determined by deducting such amount the Directors of the Management Company consider appropriate to reflect the true value thereof.
- (b) Securities listed on a stock exchange or traded on any other regulated market will be valued at the last available price on such stock exchange or market. If a security is listed on several stock exchanges or markets, the last available price on the stock exchange or market, which constitutes the main market for such securities, will be determining.
- (c) Securities not listed on any stock exchange or traded on any regulated market will be valued at their last available market price.
- (d) Securities for which no price quotation is available or for which the price referred to in (b) and/or (c) is not representative of the fair market value, will be valued prudently, and in good faith on the basis of their reasonable foreseeable sales prices.
- (e) Investments in investment funds of the open ended type are taken at their latest net asset values reported by the administrator of the relevant investment fund.
- (f) Financial futures contracts (on securities, interest rates and indices) are valued at the exchange quoted settlement price. While the contracts are open, unrealised gains and losses are recorded on "mark-to market" basis at the valuation date. When a contract is closed, the Fund records a realised gain or loss equal to the difference between the proceeds from, or cost of, the closing transaction and the price at which the contract was originally written.
- (g) Options contracts (on securities, currencies, interest rates and indices) are valued on the basis of the last available trade price.
- (h) Forward foreign exchange contracts are valued by reference to the forward rate prevailing at the valuation date.

NOTES TO THE FINANCIAL STATEMENTS

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Valuation of investments (continued)

- i) Contracts for which no price quotation is available or for which the price referred to in (g) and/or (h) is not representative of the fair market value, will be valued prudently, and in good faith on the basis of their reasonable foreseeable sales prices.
- j) For Carnegie Fund II - Biotechbridge Sub-Fund, guidelines from the European Private Equity and Venture Capital Association (EVCA) may be applied for the valuation of investments.
The Management Company has applied the Recent Investment methodology as set out in the guidelines provided by the European Private Equity and Venture Capital Association (EVCA) which can be summarized as follows:
 - All unquoted investments should be valued at cost unless a new financing round or partial sale, involving a material investment by a third party at arm's length, has taken place in which case the valuation should be based on the transaction price.
 Additionally, if any material and permanent diminution in the value of the investment below cost occurs, the investment should be written down by multiples of 25% only.
As at June 30, 2011, given the financial situation of Genizon BioSciences in the Carnegie Fund II - Biotechbridge Sub-Fund's securities portfolio, the Board of Directors of the Management Company has decided to value this holding at zero.
- k) For Carnegie Fund II - Private Equity I Sub-Fund, investments in EQT V (No.1) were valued on the basis of the quarterly reporting as at June 30, 2011, received from EQT V (No.1). For Carnegie Fund II - Private Equity II Sub-Fund, investments in EQT Infrastructure (No.1) were valued on the basis of the quarterly reporting as at June 30, 2011, received from EQT Infrastructure (No.1).

2.2 Realised profit and loss on investments

Profits and losses on sales of investments have been determined on the basis of average cost.

2.3 Foreign exchange

The combined financial statements of the Fund are maintained in SEK. The combined financial statements are the sum of the Sub-Funds' financial statements equivalent in SEK translated, where applicable, at the rate of exchange ruling as at June 30, 2011.

The market value of the investments and other assets and liabilities expressed in currencies other than the base currency of each Sub-Fund have been converted at the rates of exchange ruling as at June 30, 2011. The cost of investments in currencies other than the base currency of each Sub-Fund is converted at the rates of exchange prevailing at each Net Asset Value calculation date. Profits and losses arising from foreign exchange operations are taken to the Statement of Operations and Changes in Net Assets.

2.4 Income from investments

Dividends are recognised as income on the date securities are first quoted ex-dividend, to the extent that information thereon is reasonably available to the Sub-Fund.

Interest on bonds and cash are accrued on a daily basis.

3 EXCHANGE RATES AS AT JUNE 30, 2011

1 CAD	=	6.55232641	SEK	1 GBP	=	10.12555171	SEK
1 CHF	=	7.50898263	SEK	1 JPY	=	0.07849083	SEK
1 DKK	=	1.22722154	SEK	1 NOK	=	1.17654015	SEK
1 EUR	=	9.15360000	SEK	1 USD	=	6.32547854	SEK

NOTES TO THE FINANCIAL STATEMENTS

4 TAX STATUS

The Fund is registered under the Luxembourg law as a mutual investment fund (“Fonds Commun de Placement”). Accordingly, no Luxembourg income or capital gains tax is, at present, payable. It is subject, however, to an annual “taxe d’abonnement” calculated at the annual rate of 0.05% of the net asset value of the Fund at the end of each quarter, excluding investments in other Luxembourg funds already subject to that tax. This tax is payable quarterly.

5 FORWARD FOREIGN EXCHANGE CONTRACTS

As at June 30, 2011 the Fund had entered into the following outstanding forward foreign exchange contracts:

<u>Purchase</u>	<u>Sale</u>	<u>Maturity</u>	<u>Unrealised Result</u>
<u>Carnegie Fund II - Fund of Funds International</u>			
USD 136,155.43	SEK 862,000.00	July 5, 2011	USD (118.84)

6 BANK BORROWINGS AND PLEDGES

The Carnegie Fund II - Biotechnology Sub-Fund may borrow the equivalent of up to 25% of the total net assets for investment purposes. As at June 30, 2011 the Sub-Fund had borrowings totalling EUR 0.36 million, which represented 2.90% of the total net assets of the Sub-Fund. According to the pledge agreement entered with the Custodian on January 16, 2002, such borrowing is guaranteed by the assets of the Sub-Fund.

For all sub-funds of the Fund, the assets are pledged in favour of the Custodian to guarantee the liabilities of the sub-funds.

7 COMMITMENTS

On October 20, 2006, Carnegie Fund II - Private Equity I Sub-Fund committed to invest EUR 30,000,000.00 in EQT V (No.1). At the date of this report, the Carnegie Fund II - Private Equity I Sub-Fund has paid the equivalent of 88.82% of its initial commitment and is committed to pay the remaining EUR 3,353,943.00 upon capital call notice from the manager of EQT V (No.1).

On May 16, 2008, Carnegie Fund II - Private Equity II Sub-Fund committed to invest EUR 15,200,000.00 in EQT Infrastructure (No.1). At the date of this report, the Carnegie Fund II - Private Equity II Sub-Fund has paid the equivalent of 55.06% of its initial commitment and is committed to pay the remaining EUR 6,830,415.00 upon capital call notice from the manager of EQT Infrastructure (No.1).

8 GENERAL EXPENSES

General expenses relating to the custody and administration of the Fund are borne by the Management Company.

NOTES TO THE FINANCIAL STATEMENTS

9 MANAGEMENT FEE

The Management Company is entitled to be paid a fee based on the net assets of each Sub-Fund as determined on each valuation date. The fee is accrued daily and payable monthly. The rate of management fee applicable to each Sub-Fund, in % of the total net assets per year, is as follows:

Carnegie Fund II - Biotechbridge Sub-Fund	0.30%
Carnegie Fund II - Biotechnology Sub-Fund	1.10%
Carnegie Fund II - Fund of Funds International	0.25%
Carnegie Fund II - Swedish Large Cap Sub-Fund	1.60%
Carnegie Fund II - Swedish Small Cap Sub-Fund	1.60%

For Carnegie Fund II - Private Equity I Sub-Fund, the Management Company is entitled to an annual management fee equal to (i) 1% per annum of the total Commitments of all of the Unitholders in Carnegie Fund II - Private Equity I Sub-Fund until the sixth anniversary of the first closing date, or such earlier date when the commitment period in EQT V expires and (ii) following the sixth anniversary of the first closing date, or such earlier date when the commitment period in EQT V expires, until the liquidation of the Sub-Fund, 1% of the Net Asset Value of all Units in the Sub-Fund. The management fee shall be paid by the Unitholders on a pro rata basis based on ownership of Units in the Sub-Fund, quarterly in advance.

For Carnegie Fund II - Private Equity II Sub-Fund, the Management Company is entitled to an annual management fee equal to (i) 1% per annum of the total Commitments of all of the Unitholders in Carnegie Fund II - Private Equity II Sub-Fund until the sixth anniversary of the first closing date, or such earlier date when the commitment period in EQT Infrastructure expires and (ii) following the sixth anniversary of the first closing date, or such earlier date when the commitment period in EQT Infrastructure expires, until the liquidation of the Sub-Fund, 1% of the Net Asset Value of all Units in the Sub-Fund. The management fee shall be paid by the Unitholders on a pro rata basis based on ownership of Units in the Sub-Fund, quarterly in advance.

10 PERFORMANCE FEE

The Management Company is entitled to an annual performance fee, accrued monthly, from the Carnegie Fund II - Biotechnology Sub-Fund's assets which is due as of the end of each fiscal year. The performance fee for any fiscal year is an amount equal to 20% of the net realised and unrealised appreciation, if any, in the Net Asset Value of the Units of the Fund (adjusted for the sale and redemption of Units) during the fiscal year, but only in the event the Sub-Fund's Net Asset Value has increased for that fiscal year and cumulatively since the issuance of Units by at least 5% per annum (pro-rated for a partial year). The Management Company is also entitled to an additional performance fee in respect of units issued during a fiscal year at a time when the Net Asset Value per Unit is less than the Net Asset Value at the beginning of the year. These adjustments are effected by redeeming a sufficient number of those Units at the end of the fiscal year so that the particular Unitholder is charged the appropriate performance fee.

The Management Company is entitled to an annual performance fee, accrued monthly, from the assets of Carnegie Fund II - Biotechbridge Sub-Fund which is due as of the end of each fiscal year. The performance fee for any fiscal year is an amount equal to 20% of the net realised and unrealised appreciation, if any, in the Net Asset Value of the Units during each fiscal year of the Sub-Fund, but only in the event the Sub-Fund's Net Asset Value has increased for that fiscal year by at least 5% per annum (pro rated for a partial year) after taking into account the annual management fee. In case of Net Losses allocable to the Sub-Fund during any fiscal year and in case that during a subsequent fiscal year there is a Net Profit allocable to the Sub-Fund there will be no performance fee payable until the amount of Net Losses has been recouped.

The Management Company will, if applicable, charge a performance fee in Carnegie Fund II - Private Equity I Sub-Fund and Carnegie Fund II - Private Equity II Sub-Fund equal to 8% of all proceeds received by the Sub-Fund following the point of time when the Sub-Fund has repaid the Unitholders all amounts drawn down from the Unitholders.

The performance fee mechanisms are described in detail in the Fund's Prospectus.